Literature DB >> 22709520

Licensure of vaccines using the Animal Rule.

Drusilla L Burns1.   

Abstract

A number of new vaccines are being developed against microbial pathogens that might be used as bioweapons. For some of these vaccines, because of the lack of endemic disease and the lethal nature of the disease, human efficacy studies would not be ethical or feasible to conduct. In such cases, a regulation, known as the 'Animal Rule', can be used which allows the United States Food and Drug Administration to consider appropriate animal studies as evidence of effectiveness of a vaccine. Using this rule, pathways to licensure are being developed for new vaccines against bioweapons based on well-designed animal studies. The results of those animal protection studies together with the best scientific information available concerning immune mechanisms of protection allow protection in the animals to be bridged to effectiveness in humans, usually through the use of an appropriate immune marker. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22709520     DOI: 10.1016/j.coviro.2012.01.004

Source DB:  PubMed          Journal:  Curr Opin Virol        ISSN: 1879-6257            Impact factor:   7.090


  18 in total

1.  Correlation between anthrax lethal toxin neutralizing antibody levels and survival in guinea pigs and nonhuman primates vaccinated with the AV7909 anthrax vaccine candidate.

Authors:  Vladimir Savransky; Jeffry D Shearer; Melicia R Gainey; Daniel C Sanford; Gloria S Sivko; Gregory V Stark; Na Li; Boris Ionin; Michael J Lacy; Mario H Skiadopoulos
Journal:  Vaccine       Date:  2017-07-31       Impact factor: 3.641

Review 2.  Current trends in West Nile virus vaccine development.

Authors:  Ian J Amanna; Mark K Slifka
Journal:  Expert Rev Vaccines       Date:  2014-04-01       Impact factor: 5.217

Review 3.  Drugs derived from phage display: from candidate identification to clinical practice.

Authors:  Andrew E Nixon; Daniel J Sexton; Robert C Ladner
Journal:  MAbs       Date:  2014 Jan-Feb       Impact factor: 5.857

4.  Evaluation of immunogenicity and efficacy of anthrax vaccine adsorbed for postexposure prophylaxis.

Authors:  Boris Ionin; Robert J Hopkins; Brett Pleune; Gloria S Sivko; Frances M Reid; Kristin H Clement; Thomas L Rudge; Gregory V Stark; Alison Innes; Suha Sari; Tina Guina; Cris Howard; Jeffrey Smith; M Lisa Swoboda; Ekaterina Vert-Wong; Virginia Johnson; Gary S Nabors; Mario H Skiadopoulos
Journal:  Clin Vaccine Immunol       Date:  2013-05-08

5.  Current strategic thinking for the development of a trivalent alphavirus vaccine for human use.

Authors:  Daniel N Wolfe; D Gray Heppner; Shea N Gardner; Crystal Jaing; Lesley C Dupuy; Connie S Schmaljohn; Kevin Carlton
Journal:  Am J Trop Med Hyg       Date:  2014-05-19       Impact factor: 2.345

Review 6.  What Is the Predictive Value of Animal Models for Vaccine Efficacy in Humans? The Importance of Bridging Studies and Species-Independent Correlates of Protection.

Authors:  Hana Golding; Surender Khurana; Marina Zaitseva
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-04-02       Impact factor: 10.005

Review 7.  Designing tomorrow's vaccines.

Authors:  Gary J Nabel
Journal:  N Engl J Med       Date:  2013-02-07       Impact factor: 91.245

8.  Modified Vaccinia Ankara Virus Vaccination Provides Long-Term Protection against Nasal Rabbitpox Virus Challenge.

Authors:  Dorothy I Jones; Charles E McGee; Christopher J Sample; Gregory D Sempowski; David J Pickup; Herman F Staats
Journal:  Clin Vaccine Immunol       Date:  2016-07-05

Review 9.  Vaccinating against monkeypox in the Democratic Republic of the Congo.

Authors:  Brett W Petersen; Joelle Kabamba; Andrea M McCollum; Robert Shongo Lushima; Emile Okitolonda Wemakoy; Jean-Jacques Muyembe Tamfum; Beatrice Nguete; Christine M Hughes; Benjamin P Monroe; Mary G Reynolds
Journal:  Antiviral Res       Date:  2018-11-14       Impact factor: 5.970

10.  Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome.

Authors:  Shibo Jiang; Maria Elena Bottazzi; Lanying Du; Sara Lustigman; Chien-Te Kent Tseng; Elena Curti; Kathryn Jones; Bin Zhan; Peter J Hotez
Journal:  Expert Rev Vaccines       Date:  2012-12       Impact factor: 5.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.